pioneer 2 semaglutide Overview of the global clinical trial program for oral Efficacy and safety of once-daily

Webinars for Insurance Agents Get Connected: Register with Ritter Insurance Marketing the FMO that powers the Agent Survival Guide Podcast

In recent years, the landscape of weight management has rapidly evolved, especially for women navigating midlife hormonal changes

However, no retrospective epidemiological studies can provide definitive answers, and nausea, vomiting and diarrhoea remain the most clinically relevant adverse effects of these drugs, compromising long-term adherence.

Easy Printable Wellness Tools

GLP-1 medications are everywhere right now, but the conversation around them often lacks nuance and is rarely discussed through the lens of active people

The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.Weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014.